Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)PDM09 from Canada's sentinel surveillance network, January 2014

Eurosurveillance

Volumn 19, Issue 5, 2014, Pages

  Skowronski, D M ^a,b   Chambers, C ^a   Sabaiduc, S ^a   De Serres, G ^c,d,e   Dickinson, J A ^f   Winter, A L ^g   Fonseca, K ^f,h   Gubbay, J B ^g,i   Charest, H ^c   Petric, M ^a,b   Krajden, M ^a,b   Mahmud, S M ^j,k   Van Caeseele, P ^k,l   Kwindt, T L ^a,b   Eshaghi, A ^g   Bastien, N ^m   Li, Y ^k,m  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g PUBLIC HEALTH ONTARIO   (Canada)

^h Alberta Provincial Laboratory   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

^l CADHAM PROVINCIAL LABORATORY   (Canada)

^m PUBLIC HEALTH AGENCY OF CANADA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; AVIAN INFLUENZA; CANADA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; NOSE SMEAR; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENTINEL SURVEILLANCE; SORE THROAT; VIRUS CHARACTERIZATION; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NASOPHARYNX; NOSE; OUTCOME ASSESSMENT (HEALTH CARE); REAL-TIME POLYMERASE CHAIN REACTION; SEASONS; SENSITIVITY AND SPECIFICITY; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VACCINATION;

EID: 84893521789     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.5.20690     Document Type: Article

References (43)

1. Public Health Agency of Canada (PHAC). FluWatch. Weekly reports 2013-2014 season. Ottawa: PHAC. [Accessed: 1 Feb 2014]. Available from: http://www.phac-aspc.gc.ca/fluwatch/13-14/index-eng.php
2. Centers for Disease Control and Prevention (CDC). FluView. 2013-2014 influenza season week 4 ending January 25, 2014. U.S. Virologic Surveillance. Atlanta: CDC. [Accessed: 29 Jan 2014]. Available from: http://www.cdc.gov/flu/weekly/pastreports.htm
3. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, Mahmud SM, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):pii=20394.
4. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed: 29 Jan 2014]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/en/index.html
5. Skowronski DM, Gilbert M, Tweed SA, Petric M, Li Y, Mak A, et al. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Can Commun Dis Rep. 2005;31(18):181-91.
6. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25(15):2842-51. http://dx.doi.org/10.1016/j.vaccine.2006.10.002
7. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199(2):168-79. http://dx.doi.org/10.1086/595862
8. Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of influenza vaccine effectiveness for 2007-08 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis. 2012;205(12):1858-68. http://dx.doi.org/10.1093/infdis/jis283
9. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med. 2010;7(4):e1000258. http://dx.doi.org/10.1371/journal.pmed.1000258
10. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, et al. Effectiveness of AS03-adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ. 2011;342:c7297. http://dx.doi.org/10.1136/bmj.c7297
11. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis. 2012;55(3):332-42. http://dx.doi.org/10.1093/cid/cis431
12. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter A-L, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014 Jan 19. [Epub ahead of print]. http://dx.doi.org/10.1093/infdis/jiu048
13. Brownlee GG, Fodor E. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B Biol Sci. 2001;356(1416):1871-6. http://dx.doi.org/10.1098/rstb.2001.1001
14. Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490. http://dx.doi.org/10.1371/journal.pone.0009490
15. Rambaut A. FigTree v1.4.0: a graphical viewer of phylogenetic trees. Edinburgh: University of Edinburgh. [Accessed: 29 Jan 2014]. Available from: http://tree.bio.ed.ac.uk/software/figtree/
16. Statistics Canada. Influenza immunization, less than one year ago by sex, by province and territory (Percent). Ottawa: Statistics Canada. [Accessed: 29 Jan 2014]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health102b-eng.htm
17. Gilmour H and Hofmann N. H1N1 vaccination. Health Reports. 2010;21(4). Catalogue no. 82-003-XPE. Ottawa: Statistics Canada. [Accessed: 29 Jan 2014]. Available from: http://www.statcan.gc.ca/pub/82-003-x/2010004/article/11348-eng.pdf
18. Broemeling AM, Watson DE, Prebtani F. Population patterns of chronic health conditions, co-morbidity and healthcare use in Canada: implications for policy and practice. Healthc Q. 2008;11(3):70-6. http://dx.doi.org/10.12927/hcq.2008.19859
19. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-83. http://dx.doi.org/10.1586/eri.11.51
20. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Summary Europe, December 2013. Surveillance report. Stockholm: ECDC. 2014. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-dec-2013.pdf
21. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLOS One. 2014. Forthcoming.
22. Yang H, Carney P, Stevens J. Structure and receptor binding properties of a pandemic H1N1 virus hemagglutin. Version 2. PLoS Curr. 2010 March 22 [revised 2010 March 23];2:RRN1152.
23. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. http://dx.doi.org/10.1126/science.1244730
24. Soundarajan V, Zheng S, Patel N, Warnock K, Raman R, Wilson IA, et al. Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation. Sci Rep. 2011;1:200. http://dx.doi.org/10.1038/srep00200
25. Khandaker I, Suzuki A, Kamigaki T, Tohma K, Odagiri T, Okada T, et al. Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011. Virus Genes. 2013 Sep 29. [Epub ahead of print]. http://dx.doi.org/10.1007/s11262-013-0980-5
26. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One. 2011;6(8):e23085. http://dx.doi.org/10.1371/journal.pone.0023085
27. Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, et al. Effectiveness of 1 dose of influenza A(H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. J Infect Dis. 2012;206(7):1059-68. http://dx.doi.org/10.1093/infdis/jis441
28. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. 2011;6(11):e27622. http://dx.doi.org/10.1371/journal.pone.0027622
29. Martínez-Baz I, Martinez-Argola V, Reina G, Guevara M, Cenoz MG, Moran J, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health. 2013;13:191. http://dx.doi.org/10.1186/1471-2458-13-191
30. Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012;30(24):3595-602. http://dx.doi.org/10.1016/j.vaccine.2012.03.048
31. Pebody RG, Andrews N, Fleming DM, McMenamin J, Cottrell S, Smyth B, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect. 2012 Jun 13:1-11. [Epub ahead of print].
32. Valenciano M, Kissling E, I-MOVE case-control study team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):pii=20400.
33. Treanor JJ, Talbot K, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012;55(7):951-9. http://dx.doi.org/10.1093/cid/cis574
34. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58(3):319-27. http://dx.doi.org/10.1093/cid/cit736
35. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis. 2013;207(8):1262-9. http://dx.doi.org/10.1093/infdis/jit020
36. Influenza Research Database. World Health Organization recommendations for composition of influenza vaccines. [Accessed: 5 Feb 2014]. Available from: http://www.fludb.org/brc/vaccineRecommend.do?decorator=influenza
37. Skowronski DM, Chambers C, Janjua NZ, Petric M, Krajden M. A(H1N1)pdm09-Canada: (British Columbia) primary data and analysis. ProMED Archive Number 20140101.2146429. 1 Jan 2014. Available from: http://www.promedmail.org/direct.php?id=2146429
38. Bansal S, Pourbohloul B, Hupert N, Grenfell B, Meyers LA. The shifting demographic landscape of pandemic influenza. PLoS One. 2010;5(2):e9360. http://dx.doi.org/10.1371/journal.pone.0009360
39. Orenstein EW, De Serres G, Haber MJ, Shay D K, Bridges C B, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36(3):623-31. http://dx.doi.org/10.1093/ije/dym021
40. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised double-blind placebo-controlled trials. Euro Surveill. 2013;18(37):pii:20585.
41. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA. 1999;96(24):14001-6. http://dx.doi.org/10.1073/pnas.96.24.14001
42. Pebody R, Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011;16(6):pii=19791.
43. National Advisory Committee on Immunization. Statement on seasonal influenza vaccine for 2013-2014. Can Commun Dis Rep. 2013;39:1-37. ISSN 1481-8531. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/index-eng.php